| Catalog No. | VK623056 |
|---|
| Species reactivity | Zaire ebolavirus (ZEBOV) |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Human |
|---|
| Isotype | IgG1, kappa |
|---|
| Biological activity |
Maftivimab binds with high affinity to the recombinant histidine-tagged extracellular domain protein of Ebola virus Makona strain glycoprotein (K d = 2.97 × 10 nM [1]). Maftivimab potently neutralizes Ebola pseudovirus particles in vitro, with an IC 50 of 0.17 nM [1]. |
| Expression system |
Mammalian cells |
| Clonality |
Monoclonal |
| Target |
Envelope glycoprotein, GP1, 2, GP, Shed GP, GP1, 2-delta, GP1, GP2, GP |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Accession |
Q05320 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternate Names | REGN-3470-3471-3479, REGN-3470/REGN-3471/REGN-3479, INMAZEB™(odesivimab-ebgn, maftivimab, andatoltivimab), 2135632-36-7 |
|---|
| Background | Envelope glycoprotein (GP) is a ~74 kDa protein. Trimeric GP1,2 complexes form the virion surface spikes and mediate the viral entry processes, with GP1 acting as the receptor-binding subunit and GP2 as the membrane fusion subunit. At later times of infection, down-regulates the expression of various host cell surface molecules that are essential for immune surveillance and cell adhesion. Down-modulates several integrins including ITGA1, ITGA2, ITGA3, ITGA4, ITGA5, ITGA6, ITGAV and ITGB1. This decrease in cell adhesion molecules may lead to cell detachment, contributing to the disruption of blood vessel integrity and hemorrhages developed during infection (cytotoxicity) (Probable). Interacts with host TLR4 and thereby stimulates the differentiation and activation of monocytes leading to bystander death of T-lymphocytes. 1. Simmons, G. et al. (2002) Journal of virology 76, 2518-28. PMID: 118364303. Iampietro, M. et al. (2017) PLoS pathogens 13, e1006397. PMID: 285425764. Edri, A. et al. (2018) Frontiers in immunology 9, 1428. PMID: 300135496. Brinkmann, C. et al. (2016) Journal of virology 90, 11075-11086. PMID: 277079247. González-Hernández, M. et al. (2018) Journal of virology 92. PMID: 29669839 |
|---|
| References |
1. Markham A. REGN-EB3: First Approval. Drugs. 2021 Jan;81(1):175-178. [VK623056]
2. Gaudinski MR, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet. 2019 Mar 2;393(10174):889-898. [VK623056] |
| Note |
For research use only. Not suitable for clinical or therapeutic use. |
中文
English
한국어
日本語
Español
Français
Русский
